Intranasal foralumab, developed by biotech company ... million grant from the National Institute on Aging to study the nasal spray for Alzheimer’s, just a few months after the FDA approved ...

The secondary cascade, although a normal physiological response, can contribute to ongoing neuroinflammation, oxidative ...

The randomized, double-blind, placebo-controlled trial aims to assess the safety, tolerability, and efficacy of intranasal foralumab in ... Tiziana’s innovative nasal approach has the potential ...

The randomized, double-blind, placebo-controlled trial is assessing the safety, tolerability, and efficacy of intranasal foralumab ... through its innovative nasal delivery technology.

which comes in the form of a nasal spray, to target the neuroinflammatory process. When they tested the antibody – known as ...

Albers and colleagues are interested in whether olfactory dysfunction — the sometimes-subtle loss of sense of smell — can serve as an early warning sign for neurodegenerative diseases such as ...

In a study published in Nature Neuroscience, researchers from Tiziana Life Sciences Ltd. and collaborators investigated the potential of nasal delivery of the CD3 foralumab to reduce neuroinflammation ...

NEW YORK, April 02, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation ...

Morningstar brands and products Company Portfolio ...

Tiziana’s innovative nasal approach has the potential to provide an improvement in efficacy as well as safety and tolerability compared to intravenous (IV) delivery. Tiziana’s lead candidate, ...

NEW YORK, April 02, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with ...